Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indacaterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 19/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 10/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.98 |
| ▸ | HTR2A | P28223 | 1/20 | 0.98 |
| ▸ | HTR2C | P28335 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | SRSF6 | Q13247 | 1/20 | 0.98 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.98 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.98 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indacaterol SCHEMBL3664612 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL867570 | 1.00 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL159597 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29798949 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29367297 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4186345 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL48098 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL29350045 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012030 | 0.98 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A | |
| Indacaterol SCHEMBL4012026 | 0.98 | ADRB2 (0.98) | ADRB2ADRB1SLC6A2ADRA1DHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2332915-B1 | Beta2-adrenoceptor agonists | NOVARTIS AG (CH) | 2013-02-27 | — | — | EP | claimed |
| US-20120316142-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | LOHSE OLIVIER (FR) | 2012-12-13 | — | — | US | claimed |
| EP-2228064-A2 | Pharmaceutical composition containing glycopyrrolate and a beta2 adrenoceptor agonist | Novartis AG (CH) | 2010-09-15 | — | — | EP | claimed |
| EP-1183240-B1 | BETA2-ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2009-08-19 | — | — | EP | claimed |
| EP-2044025-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | Novartis AG (CH) | 2009-04-08 | — | — | EP | claimed |
| US-20080286363-A1 | (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate; 3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (glycopyrrolate), and a glucocorticosteroids | COLLINGWOOD STEPHEN PAUL | 2008-11-20 | — | — | US | claimed |
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | NXP B.V. (NL) | 2008-11-13 | — | — | US | claimed |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | claimed |
| EP-1965792-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAYS DISEASES | Novartis AG (CH) | 2008-09-10 | — | — | EP | claimed |
| EP-1957072-A1 | TREATMENT OF ASTHMA AND COPD USING TRIPLE-COMBINATION THERAPY | Novartis AG (CH) | 2008-08-20 | — | — | EP | claimed |
| WO-2008074856-A1 | COMBINATION THERAPY FOR THE TREATMENT OF AIRWAYS DISEASE | NOVARTIS AG (CH) | 2008-06-26 | — | — | WO | claimed |
| EP-1878722-A1 | Quinolinone derivatives and their pharmaceutical compositions | Novartis AG (CH) | 2008-01-16 | — | — | EP | claimed |
| WO-2008000839-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | NOVARTIS AG (CH) | 2008-01-03 | — | — | WO | claimed |
| JP-2007538036-A | — | — | 2007-12-27 | — | — | JP | claimed |
| WO-2007057219-A1 | TREATMENT OF ASTHMA AND COPD USING TRIPLE-COMBINATION THERAPY | NOVARTIS AG (CH) | 2007-05-24 | — | — | WO | claimed |
| WO-2007057221-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY AND OBSTRUCTIVE AIRWAYS DISEASES | NOVARTIS AG (CH) | 2007-05-24 | — | — | WO | claimed |
| EP-1755590-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | claimed |
| WO-2005110402-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2005-11-24 | — | — | WO | claimed |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | NOVARTIS AG (CH) | 2005-07-14 | — | — | US | claimed |
| US-6878721-B1 | N-(partially hydrogenated fused carbocycle)-2-arylethylamine derivatives, e.g., 8-hydroxy-5-(1-hydroxy-2-(indan-2-ylamino)-ethyl)-1H-quinolin-2-one; treatment of obstructive or inflammatory | NOVARTIS AG (CH) | 2005-04-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080279948-A1 | Treatment of Asthma and Copd Using Triple-Combination Therapy | MC2R, GALR3, CHRM3 | ADRB2 214/4885ADRB1 211/4885SLC6A2 3734/4885 |
| US-20120316142-A1 | QUINOLINONE DERIVATIVES AND THEIR PHARMACEUTICAL COMPOSITIONS | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885SLC6A2 301/4885 |
| US-20080286363-A1 | (R)-5-[2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one maleate; 3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide (glycopyrrolate), and a glucocorticosteroids | NR3C1, NR3C2, MGAT3 | ADRB2 38/4885ADRB1 43/4885SLC6A2 2828/4885 |
| US-20050153957-A1 | Administering an aminoindanyl derivative and; a steroid, dopamine receptor agonist or an anticholinergic or antimuscarinic agent; respiratory system disorders, antiallergens, chronic obstructive pulmonary disease, adult respiratory distress syndrome, bronchitis | ADRB3, ADRB2, ADRB1 | ADRB2 2/4885ADRB1 3/4885SLC6A2 631/4885 |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | GALR1, GALR3, GALR2 | ADRB2 94/4885ADRB1 109/4885SLC6A2 3646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.